Sign In
Buy LTRN
$3.40
-0.340 (-9.09%)
At Close: Jun 03, 2026
DALLAS, Oct. 25, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
09:00am, Thursday, 30'th Sep 2021
DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transf
DALLAS and COLUMBUS, Ohio, Sept. 28, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September
09:02am, Tuesday, 07'th Sep 2021
DALLAS, Sept. 7, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication
11:02am, Monday, 30'th Aug 2021
The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas. The news follows the recent announcement of the
Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock
03:15pm, Thursday, 19'th Aug 2021
Lantern Pharma Inc (NASDAQ: LTRN) announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve survival in animals models of glioblastoma (GBM)
DALLAS and BALTIMORE, Aug. 19, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug
DALLAS, Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
04:51pm, Wednesday, 11'th Aug 2021
The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for pancreatic cancer. LP-184 is a small molecule drug candidate and next-generation alkylating agent th
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
08:21am, Wednesday, 11'th Aug 2021
DALLAS, Aug. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
06:43am, Saturday, 31'st Jul 2021
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
DALLAS, July 27, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the
Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
02:30am, Monday, 26'th Jul 2021
Press release
Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
04:08pm, Thursday, 22'nd Jul 2021
DALLAS, July 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug
